Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036040 | 0.83 | PRMT5 (0.47) | PRMT5WDR77PDK2NAMPTKCNH2 | |
| SCHEMBL15340952 | 0.79 | PRMT5 (0.49) | PRMT5WDR77PDK2NAMPTKCNH2 | |
| SCHEMBL885907 | 0.78 | L3MBTL1 (0.59) | PRMT5WDR77PDK2NAMPTACHE | |
| SCHEMBL13537101 | 0.73 | L3MBTL1 (0.60) | PRMT5WDR77PDK2NAMPTCTSD | |
| SCHEMBL17130593 | 0.72 | PRMT5 (0.48) | PRMT5WDR77PDK2NAMPTKCNH2 | |
| SCHEMBL21054318 | 0.70 | NAMPT (0.41) | PRMT5WDR77PDK2NAMPTCTSD | |
| SCHEMBL17795050 | 0.70 | NAMPT (0.48) | PRMT5WDR77PDK2NAMPTKCNH2 | |
| SCHEMBL22643135 | 0.69 | KCNH2 (0.58) | PRMT5WDR77KCNH2ACHE | |
| SCHEMBL16911740 | 0.69 | PRMT5 (0.48) | PRMT5WDR77PDK2NAMPTKCNH2 | |
| SCHEMBL15376325 | 0.69 | PRMT5 (0.50) | PRMT5WDR77PDK2NAMPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PRMT5 1706/4885WDR77 3468/4885PDK2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.